Cargando…
Clinicians' preferences for managing aneurysmal subarachnoid hemorrhage using endothelin receptor antagonists
BACKGROUND: The endothelin receptor antagonist (ERA) clazosentan is being investigated for the medical prevention of cerebral vasospasm and associated complications, such as delayed cerebral ischemia (DCI), after aneurysmal subarachnoid hemorrhage (aSAH). This study quantified how clinicians weigh t...
Autores principales: | Heidenreich, Sebastian, Trapali, Myrto, Krucien, Nicolas, Phillips-Beyer, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017541/ https://www.ncbi.nlm.nih.gov/pubmed/36937515 http://dx.doi.org/10.3389/fneur.2023.1102290 |
Ejemplares similares
-
Endothelin-receptor antagonists for aneurysmal subarachnoid hemorrhage: an updated meta-analysis of randomized controlled trials
por: Ma, Junpeng, et al.
Publicado: (2012) -
Endothelin antagonists in subarachnoid hemorrhage: what next?
por: Macdonald, R Loch
Publicado: (2012) -
Current status of perimesencephalic non-aneurysmal subarachnoid hemorrhage
por: Hou, Kun, et al.
Publicado: (2022) -
The Role of the Blood Neutrophil-to-Lymphocyte Ratio in Aneurysmal Subarachnoid Hemorrhage
por: Cai, Lingxin, et al.
Publicado: (2021) -
Peripheral Leukocytosis and Clinical Outcomes After Aneurysmal Subarachnoid Hemorrhage
por: Shrestha, Ramesh, et al.
Publicado: (2022)